MUTATIONS IN PULMONARY ADENOCARCINOMA. FREQUENCY STUDY FROM A ONCOLOGY CENTRE IN CENTRAL KERALA.-Reference-Cited by-同舟云学术

MUTATIONS IN PULMONARY ADENOCARCINOMA. FREQUENCY STUDY FROM A ONCOLOGY CENTRE IN CENTRAL KERALA.

Published:2021-12-15 Issue: Volume: Page:21-23
ISSN:
Container-title:PARIPEX INDIAN JOURNAL OF RESEARCH
language:en
Short-container-title:PIJR

Author:

Antony Aniya¹,John T Vanesa²,Usman Sandhra³,Augustine Joy⁴

Affiliation:

1. Assistant Professor, Department Of Pathology , Amala Institute Of Medical Sciences ,amala Nagar, Thrissur, Kerala.

2. Assistant Professor, Department Of Pathology, Jubilee Mission Medical College And Research Institute, Thrissur, Kerala.

3. Senior Resident, Department Of Pathology, Mes Academy Of Medical Sciences, Palachode, Perinthalmanna, Kerala.

4. Professor &head Of Department, Department Of Pathology, Amala Institute Of Medical Sciences, Amala Nagar, Thrissur, Kerala.

Abstract

Background: Non small cell carcinomas of lung, notably adenocarcinoma is associated with genetic mutations in EGFR (chromosome 7) , ALK (chromosome 2), ROS1(chromosome 6) . The patients harbouring these mutations are greatly benefited from tyrosine kinase inhibitor targeted chemotherapy. The prevalence of these mutations in central kerala has not been studied and documented. Aim: This study aims to analyse the frequency of different mutations in lung adenocarcinomas presenting to a oncology centre in kerala. Study Design: Descriptive study. Materials And Methods: The study spanned over a period of two years from 2019-2021. A total of 169 consecutive lung adenocarcinomas were studied. PCR for EGFR was done in 89 cases and were tested for the common mutations. ALK1 IHC using ALK-D5F3 clone and ROS with ROS-D4D6 clones were done in 40 cases. Results: EGFR mutation was present in 15 cases (17.44%). The most common age range was 40-60yrs. Two most common patterns were solid and acinar. ALK and ROS 1 mutation was found in 3 cases (7.5%) and 2 cases ( 5%) respectively. 4 cases (16.66%) of EGFR mutant lung adenocarcinoma patients had metastasis.

Publisher

World Wide Journals

Reference13 articles.

1. Gupta P, Gowrishankar S, Swain M. Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns. Indian J Pathol Microbiol 2019; 62(1):24-30.

2. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24(9):2371-6.

3. Bethune G, Bethune D , Ridgway N , Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis 2010 ; 2(1):48-51.

4. Yoon HY, Ryu JS, Sim YS, Kim D, Lee SY, Choi J, Park S, Ryu YJ, Lee JH, Chang JH. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. PLoS One 2020; 13;15(2):e0228925.

5. Chatterjee K, Ray A, Chattopadhyay B. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): A report of 106 patients from Kolkata. Indian J Cancer 2017; 54(1):305-307.